Business Practice

What do companies need to consider when developing next-gen medicines for rare diseases?

We sat down to talk shop with Novo Nordisk Executive Vice President Ludovic Helfgott

One decade behind the EU, biosimilars are arriving in the US. What can we expect? Jeff Baldetti from Cardinal Health has a few ideas.

Medicines Patent Pool has joined forces with over 30 generic manufacturers to help ensure access to anti-COVID-19 medicines for all.

The Medicine Maker’s round up of the top news stories in the pharma industry in March.

We find out how technology is enabling remote inspections in the pharma industry.

Reconfigure. Redefine. Why modular cleanroom furniture is essential for a changing pharmaceutical market.

That which we call rosaimab by any other name would find regulatory approval and commercial success. Or would it?

An industry consortium is tackling one of pharma’s biggest drug-related challenges.

Sitting Down With Dolores Schendel, Chief Executive Officer and Chief Scientific Officer at Medigene.